The Posterior Uveitis drugs in development market research report provides comprehensive information on the therapeutics under development for Posterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Posterior Uveitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Posterior Uveitis by 11 companies/universities/institutes. The top development phase for Posterior Uveitis is preclinical with four drugs in that stage. The Posterior Uveitis pipeline has 12 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Posterior Uveitis pipeline products market are: Worg Pharmaceuticals Hangzhou, Priovant Therapeutics and EyePoint Pharmaceuticals.
The key targets in the Posterior Uveitis pipeline products market include Tyrosine Protein Kinase JAK1, Toll Like Receptor Family, and Non Receptor Tyrosine Protein Kinase TYK2.
The key mechanisms of action in the Posterior Uveitis pipeline product include Calcineurin Inhibitor with one drug in Preclinical. The Posterior Uveitis pipeline products include eight routes of administration with the top ROA being Intravitreal and five key molecule types in the Posterior Uveitis pipeline products market including Small Molecule, and Synthetic Peptide.
Posterior Uveitis overview
Posterior uveitis refers to intraocular inflammation in the vitreous, retina, or choroid. Chorioretinitis is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye. It is a form of posterior uveitis. Inflammation of these layers can lead to vision-threatening complications.
For a complete picture of Posterior Uveitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
